Estimated time to complete activity: 1.5 hours
Release date: Wednesday, July 17, 2013 | Expiration date: Friday, August 30, 2013
TARGET AUDIENCE
The target audience for this activity includes oncologists, hepatologists, gastroenterologists, radiation oncologists, surgical oncologists, pathologists, and other clinicians involved in the treatment of patients with HCC.
DESIGNATION OF CREDIT
PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Educational Concepts Group, LLC designates this live material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. During the period Wednesday, July 17, 2013 through Friday, August 30, 2013, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
CME CREDIT
Physicians who complete the post-activity assessment may view and print their credit letter.
POLICY ON DISCLOSURE
It is the policy of ECG that the faculty, authors, planners, and other persons who may influence content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow ECG to identify and resolve any potential conflicts of interest.
The Following Faculty Members Have Declared Relevant Financial Relationships
Ghassan Abou-Alfa, MD
Grants/Research Support
Abbott Laboratories, Amgen Inc., Bayer HealthCare Pharmaceuticals, Inc., Genentech, Inc., ImClone Systems, Novartis, Polaris Pharmaceuticals, Inc., Roche
Spouse
Abbott Laboratories, Agensys Inc., Astellas Pharma US, Inc., AstraZeneca, Momenta Pharmaceuticals, Inc., OncoMed Pharmaceuticals, Inc., sanofi-aventis
Consultant Fees
Abbott Laboratories, Amgen Inc., ArQule, Bayer HealthCare Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celsion Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Inc., Exelixis, Inc., Genentech, Inc., ImClone Systems, Jennerex Biotherapeutics, Inc., Novartis, Polaris Pharmaceuticals, Inc., Roche, Vicus Therapeutics
Spouse
Celgene Corporation, Clovis Oncology, Gilead Sciences, Inc., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Novartis, OSI Pharmaceuticals, Inc., Piramal Pharma Solutions, Polaris Pharmaceuticals, Inc., Roche, sanofi-aventis, ZIOPHARM Oncology, Inc.
Karen T. Brown, MD, FSIR
No relevant financial relationships to disclose
Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians' Desk Reference for discussion of approved indications, contraindications, and warnings.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc.
CME INQUIRIES
For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
www.educationalconcepts.net
This activity is sponsored by Educational Concepts Group, LLC
This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc./Onyx Pharmaceuticals, Inc.
![](https://s3.amazonaws.com/media.author.realcme.com/author/283281/image/Logo_bayer_onyx%20dual_Horiz_Print_4c.jpg)